![]() ![]() |
![]() ¼ÒÀ§ HIV Ç×ü °Ë»çÀÇ Ç㱸¼ºÀ» ¼³¸íÇÑ ³í¹®ÀÔ´Ï´Ù. ÀÏÀü¿¡ µ¿ÀÏ ÀúÀÚÀÇ À¯»çÇÑ ±ÛÀ» ¼Ò°³ÇÑ ¹Ù ÀÖÁö¸¸ ¹ÝüÁ¦ HIV/AIDS ÀÌ·ÐÀ» óÀ½ Á¢ÇÏ´Â ºÐµéÀÌ ±âÁ¸ÀÇ °¡¼³ÀÌ ¾È°í ÀÖ´Â ¹®Á¦°¡ ¹«¾ùÀÎÁö¸¦ ÀνÄÇÏ´Â Ãâ¹ßÁ¡À¸·Î¼ °¡Àå ÁÁÀº ÀÚ·á¶ó°í »ý°¢Çϱ⿡ º¸´Ù ÃÖ±Ù¿¡ ³ª¿Â ±ÛÀ» ¿Ã¸³´Ï´Ù. Âü°í·Î Á¦°¡ ÀÌÇØÇÑ HIV Ç×ü °Ë»çÀÇ ¹®Á¦Á¡À» °£´ÜÈ÷ ¿ä¾àÇÏ¸é ´ÙÀ½°ú °°½À´Ï´Ù. 1) Ç÷ûÀ» ºñÁ¤»óÀûÀÎ ¼öÁØÀ¸·Î Èñ¼®ÇÏÁö ¾ÊÀ¸¸é ¸ðµç »ç¶÷¿¡°Ô ¾ç¼º ¹ÝÀÀÀÌ ³ª¿Â´Ù. (1) ÀÌ´Â HIV¶ó´Â ¸®Æ®·Î¹ÙÀÌ·¯½º°¡ Á¤¸»·Î Á¸ÀçÇϰí Ç×ü °Ë»ç¿¡¼ ¹ÝÀÀÇÏ´Â Ç×ü°¡ HIV¿¡ ´ëÇÑ °ÍÀ̶ó´Â °ÍÀ» ÀÎÁ¤ÇÑ´Ù¸é ¸ðµç »ç¶÷ÀÌ HIV¿¡ °¨¿°µÈ ÀûÀÌ Àְųª °¨¿°µÇ¾î ÀÖ´Â »óÅÂÀ̾î¾ß ÇÑ´Ù. (2) ÇÏÁö¸¸ HIV¿¡ ÀÏ´Ü °¨¿°µÇ¸é ÀÚ¿¬ Ä¡À¯¶ó´Â °ÍÀº ºÒ°¡´ÉÇÑ °ÍÀ¸·Î ÁÖÀåµÇ°í ÀÖÀ¸¹Ç·Î °ú°Å¿¡ °¨¿°µÇ¾ú´ø »ç¶÷ÀÌ Ä¡À¯µÇ¾î Ç×ü¸¦ º¸À¯Çϰí ÀÖ´Ù´Â °ÍÀº ÀÖÀ» ¼ö ¾ø´Â ÀÏÀÌ´Ù. Áï ¾ç¼º ¹ÝÀÀÀÇ ¿øÀÎÀº HIV°¡ ¾Æ´Ñ ´Ù¸¥ °Í¿¡ ÀÖ´Ù. 2) Ç÷û °Ë»ç°¡ HIV Ç×ü¿¡¸¸ ƯÀÌÀûÀ¸·Î ¹ÝÀÀÇÑ´Ù´Â °ÍÀº ÀÔÁõÇÒ ¼ö ¾ø´Ù ƯÁ¤ Áúº´¿¡ ´ëÇÑ Ç×ü °Ë»çÀÇ Á¤È®¼ºÀÌ °ËÁõµÇ·Á¸é ¸ðµç ´Ù¸¥ °¡¼º ¹ÝÀÀ ¿äÀÎÀ» Á¦°ÅÇϰí ÇØ´ç º´¿øÃ¼¸¸À» ¹è¾ç ¼¼Æ÷¿¡ ÁÖÀÔÇÏ¿© ¹ÝÀÀ ¿©ºÎ¸¦ È®ÀÎÇØ¾ß ÇÑ´Ù. ÇÏÁö¸¸ Á¤ÀÛ HIV ±× ÀÚü´Â ºÐ¸®µÈ ¹Ù°¡ ¾øÀ¸¹Ç·Î HIV Ç×ü °Ë»ç¶ó´Â ÀÌ·¯ÇÑ °ËÁõ ÀýÂ÷ ÀÚü°¡ ºÒ°¡´ÉÇÏ´Ù. Áï Ç×ü°¡ ´Ü ÇϳªÀÇ º´¿øÃ¼¿¡ ´ëÇØ¼¸¸ ÀÏ´ëÀÏ ¹ÝÀÀÇÏ´Â °ÍÀº ¾Æ´Ï¸ç ½ÇÁ¦·Î ¹ÝÀÀÀ» À¯¹ß½ÃŰ´Â ¼ö¸¹Àº ¿ä¼ÒµéÀÌ Á¸ÀçÇÑ´Ù´Â Á¡¿¡¼ HIV Ç×ü °Ë»ç¿¡¼ ¾ç¼º ¹ÝÀÀÀ̶ó´Â °Í°ú HIV °¨¿°°£¿¡´Â ¾Æ¹« ¿¬°ü¼ºÀ» ÀÔÁõÇÒ ¼ö ¾ø´Ù. ========================================================================================== ¸ðµç »ç¶÷ÀÌ HIV¿¡ ´ëÇÑ ELISA Å×½ºÆ®¿¡¼ ¾ç¼º ¹ÝÀÀÀ» º¸Àδ٠Robert Giraldo ÁöÀ½ Continuum °Ü¿ïÈ£ 1998/9³â ³ª´Â Áö³ 6 ³â µ¿¾È ´º¿å½Ã¿¡ ÀÖ´Â °¡Àå ¸í¸Á ³ôÀº ´ëÇб³ º´¿øµéÁß ÇϳªÀÎ ÀÓ»ó ¸é¿ªÇÐ ½ÇÇè½Ç¿¡¼ ±Ù¹«ÇؿԴÙ. À̰÷¿¡¼ ³ª´Â °³ÀÎÀûÀ¸·Î HIV »óÅÂÀÇ Áø´ÜÀ» À§ÇÏ¿© »ç¿ëµÇ´Â ÇöÇàÀÇ Å×½ºÆ®µé, Áï ELISA, Western Blot ±×¸®°í Viral Load Å×½ºÆ®¸¦ ¼öÇàÇÏ°í »ó¼¼È÷ ¾Ë°Ô µÇ´Â ±âȸ¸¦ ¾ò¾ú´Ù. 1. ELISA Å×½ºÆ®¸¦ À§ÇÑ Ç÷ûÀÇ Èñ¼®. ELISA Å×½ºÆ®´Â Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º ȤÀº HIVÀ̶ó°í ÃßÁ¤µÇ´Â °ÍÀÇ Ç×ü¿¡ ´ëÇÑ Å×½ºÆ®ÀÌ´Ù. ÀÌ Å×½ºÆ®¸¦ Çϱâ À§Çؼ´Â Ưº°ÇÑ Ç¥º» Èñ¼®Á¦¸¦ °¡Áö°í 1:400ÀÇ ºñÀ²·Î °³ÀÎÀÇ Ç÷ûÀ» Èñ¼®Çؾ߸¸ ÇÑ´Ù. Å×½ºÆ® ŰƮ Á¦ÀÛÀÚ¿¡ ÀÇÇϸé ÀÌ Èñ¼®Á¦´Â 0,1%ÀÇ triton X-100, ¼Ò¿Í ¿°¼ÒÀÇ Ç÷û(ÃÖ¼Ò5%ÀÇ ³óÃà) ±×¸®°í Àΰ£ T Àӯı¸ ¿ëÇØÁú (ÃÖ¼Ò1:7500ÀÇ ³óµµ). ¹æºÎÁ¦: 0.1% Sodium Azide¸¦ Æ÷ÇÔÇϰí ÀÖ´Ù. (1) ÀÌ ºñÁ¤»óÀûÀ¸·Î ³ôÀº Ç÷ûÀÇ Èñ¼®[400 ¹è]Àº ³ª¿¡°Ô ³î¶ó¿òÀ» ÁÖ¾ú´Ù. ¼¼±Õ¿¡ ´ëÇÑ Ç×üÀÇ Á¸À縦 È®ÀÎÇÏ´Â ´ëºÎºÐÀÇ Ç÷û Å×½ºÆ®´Â ¼ø¼öÇÑ Ç÷û[Èñ¼®ÇÏÁö ¾ÊÀº]À» »ç¿ëÇÑ´Ù. ¿¹¸¦ µé¸é, AÇü ±×¸®°í BÇü °£¿° ¹ÙÀÌ·¯½º, dzÁø ¹ÙÀÌ·¯½º, ¸Åµ¶, hystoplasma ±×¸®°í cryptococus¿¡ ´ëÇÑ Ç×ü¸¦ È®ÀÎÇÏ´Â Å×½ºÆ®¿¡¼´Â Èñ¼®ÇÏÁö ¾ÊÀº Ç÷ûÀ» »ç¿ëÇÑ´Ù. ±×·¯³ª À§¾ç¼º ¹ÝÀÀÀ» ¹æÁöÇϱâ À§ÇÏ¿© ÀϺΠÇ÷û Å×½ºÆ®´Â Èñ¼®µÈ Ç÷ûÀ» »ç¿ëÇϴµ¥ ¿¹¸¦ µé¸é È«¿ª, ¼öµÎ ±×¸®°í ÀÌÇϼ±¿° ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ Ç×ü¸¦ È®ÀÎÇÏ´Â Å×½ºÆ®¿¡¼´Â 1:16À¸·Î Èñ¼®Çϰí cytomegalo ¹ÙÀÌ·¯½º[CMV]¿¡¼´Â 1:20, Epstein-Barr ¹ÙÀÌ·¯½º[EBV]¿¡¼´Â 1:10À¸·Î Èñ¼®ÇÑ´Ù. ¸í¹éÇÑ Àǹ®Àº ¹«¾ùÀÌ Å×½ºÆ®¿¡¼ 400¹è±îÁö Èñ¼®ÀÌ ÇÊ¿äÇÒ ¸¸Å HIV¸¦ µ¶Æ¯ÇÏ°Ô ¸¸µå´Â °ÍÀϱî? ±×¸®°í Ç÷ûÀ» Èñ¼®ÇÏÁö ¾Ê´Â´Ù¸é ¾î¶²ÀÏÀÌ ¹ß»ýÇÒ °ÍÀΰ¡?¶ó´Â Á¡ÀÌ´Ù. 2. Ç÷ûÀ» Èñ¼®ÇÏÁö ¾Ê°í ELISA Å×½ºÆ®¸¦ Å×½ºÆ®ÇÏ´Ù. ÀÌ Àǹ®µé¿¡ ´äÇϱâ À§ÇÏ¿© ³ª´Â ´º¿åÀÇ Yorktown Heights¿¡ ÀÖ´Â ÀÇÇÐ ½ÇÇè½Ç¿¡¼ ½ÇÇèÀ» ÇÏ¿´´Ù. ¼¼°èÀûÀ¸·Î ´ëºÎºÐÀÇ ÀÓ»ó ½ÇÇè½Ç¿¡¼ ELISA Å×½ºÆ®¸¦ Çϴµ¥ ÀÖ¾î ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â µ¿ÀÏÇÑ Å×½ºÆ® ½Ã¾àÀ» »ç¿ëÇÏ¿© Å×½ºÆ®¸¦ ¼öÇàÇß´Ù. (1) ù¹øÂ°·Î 1:400 Èñ¼® »óÅ¿¡¼ HIV À½¼º ÆÇÁ¤À» ¹ÞÀº Ç÷¾× »ùÇÃÀ» ¼±ÅÃÇß´Ù. ±× ´ÙÀ½ µ¿ÀÏÇÑ Ç÷û »ùÇÃÀ» °¡Áö°í ´Ù½Ã Å×½ºÆ®¸¦ Çߴµ¥ À̹ø¿¡´Â Èñ¼®À» ÇÏÁö ¾ÊÀº »óÅ¿´´Ù. Èñ¼®ÇÏÁö ¾ÊÀº »óÅ·ΠÅ×½ºÆ®¸¦ ÇÏÀÚ ¸ðµÎ ¾ç¼º ¹ÝÀÀÀ» ³ªÅ¸³»¾ú´Ù. ±× ÀÌ·¡ ´ë·« 100 °¡Áö °ßº»À» °¡Áö°í °Ë»çÇߴµ¥ Ç×»ó °°Àº °á°ú¸¦ ¾ò¾ú´Ù. ½ÉÁö¾î ³ª ÀÚ½ÅÀÇ Ç÷¾×À» °¡Áö°í °Ë»ç¸¦ Çߴµ¥ 1:400¿¡¼ À½¼º ¹ÝÀÀÀ» º¸¿´´Ù. 1:1[ Èñ¼®ÇÏÁö ¾ÊÀº »óÅÂ]¿¡¼´Â ¾ç¼º ¹ÝÀÀÀ» º¸¿´´Ù. ³ª ÀÚ½ÅÀÇ Ç÷¾×À» Á¦¿ÜÇϰí´Â ȯÀÚ »ùÇõéÀº ¸ðµÎ HIV Å×½ºÆ®¸¦ ¿äûÇÑ ÀÇ»çµé·ÎºÎÅÍ ¿Â °ÍµéÀ̾ú´Ù. µû¶ó¼ ³»°¡ Å×½ºÆ®ÇÑ ´ëºÎºÐÀÇ Ç÷¾× »ùÇõéÀº AIDSÀÇ À§ÇèÀÌ ÀÖ´Â °³ÀεéÀÇ °ÍÀÏ °ÍÀÌ´Ù. Abbott ½ÇÇè½Ç¿¡ ÀÇÇϸé, Èí¼öÄ¡[Ȳ»öÀÇ °µµ]´Â ±× ±¸½½Ã¼¿¡ °áÇÕÇÏ´Â HIV-1 Ç×üÀÇ ¾ç¿¡ ºñ·ÊÇÏ¿© Áõ°¡ÇÑ´Ù. (1) ³»°¡ ÁÖ¸ñÇÑ °ÍÀº Èñ¼®µÇ¾úÀ» ¶§[1:400] À½¼º ÆÇÁ¤À» ¹Þ¾ÒÁö¸¸ Èñ¼®ÇÏÁö ¾Ê¾ÒÀ» ¶§[1:1]´Â ¾ç¼ºÀÎ °ßº»ÀÇ Èí¼öÄ¡´Â, Èñ¼®µÇ¾ú°í ELISA¿Í Western Blot Å×½ºÆ® ¸ðµÎ¿¡¼ ¾ç¼º ¹ÝÀÀÀ» º¸ÀÎ »ùÇú¸´Ù ³·Àº ¼öÄ¡¸¦ º¸¿´´Ù´Â °ÍÀ̾ú´Ù.À̰ÍÀº ¾Æ¸¶ Èñ¼®Çϸé À½¼ºÀÌÁö¸¸ Èñ¼®ÇÏÁö ¾ÊÀ¸¸é ¾ç¼ºÀÎ Ç÷¾×ÀÇ ¾çÂÊ ¸ðµÎ ¾ç¼ºÀÎ Èñ¼®µÈ Ç÷¾×º¸´Ù ³·Àº ¼öÁØÀÇ Ç×ü¸¦ °¡Áö°í ÀÖ°í ±×·¸±â ¶§¹®¿¡ Western blot Å×½ºÆ®¿¡¼´Â À½¼º ÆÇÁ¤À» ¹ÞÀ» °ÍÀÌ´Ù¶ó´Â °ÍÀ» ÀǹÌÇÑ´Ù. ÇÏÁö¸¸ ³ª´Â ÀÌ °¡¼³À» È®ÀÎÇÒ ±âȸ¸¦ °®Áö ¸øÇß´Ù. ¾Æ·¡ µµÇ¥´Â 1:400 ºñÀ²¿¡¼´Â HIV¿¡ ´ëÇÏ¿© À½¼º ¹ÝÀÀÀ» º¸ÀÌ´Â Ç÷¾×ÀÌ ¾î¶»°Ô 1:1[Èñ¼®ÇÏÁö ¾ÊÀº »óÅÂ]¿¡¼´Â Ç×»ó ¾ç¼ºÀ¸·Î º¯ÇÏ´ÂÁö¸¦ º¸¿©ÁÖ°í ÀÖ´Ù. ================================================== µÎ »óÀÌÇÑ Ç÷û ³óÃàÀ²¿¡ µû¸¥ HIV¿¡ ´ëÇÑ ELISA Å×½ºÆ® __________________________________________________ (a) 1:400¿¡¼ÀÇ °á°ú | (b) 1:1¿¡¼ÀÇ °á°ú ---------------------- |------------------------- 9112324b G5 0.076 --- | 9112324b G5 0.262 reactive 9112325b H1 0.081 --- | 9112325b H1 0.259 reactive 9112326b H2 0.071 --- | 9112326b H2 0.329 reactive 9112327b H3 0.060 --- | 9112327b H3 0.401 reactive 9112328b H4 0.073 --- | 9112328b H4 0.345 reactive 9112329b H5 0.062 --- | 9112329b H5 0.343 reactive 9112330b J1 0.060 --- | 9112330b J1 0.234 reactive 9112331b J2 0.077 --- | 9112331b J2 0.306 reactive 9112332b J3 0.067 --- | 9112332b J3 0.248 reactive 9112333b J4 0.086 --- | 9112333b J4 0.222 reactive =================================================== ¿ (a)´Â 1:400 Èñ¼®¿¡¼ À½¼º ¹ÝÀÀÇÏ´Â 10 °¡Áö °ßº»µéÀ» º¸¿©ÁÖ°í ÀÖ´Ù. ¿ (b)´Â 1:1 Èñ¼®¿¡¼ ¾ç¼º ¹ÝÀÀÇÏ´Â °ßº»µéÀ» º¸¿©ÁÖ°í ÀÖ´Ù. HIV Ç×ü Å×½ºÆ®¸¦ À§ÇÑ Western Blot¿¡¼µµ Èñ¼®µÈ Ç÷ûÀ» ÇÊ¿ä·Î ÇÑ´Ù´Â °ÍÀ» ÁÖ¸ñÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù. ÀÌ ¶ÇÇÑ ÀϹÝÀûÀ¸·Î ³ôÀº Èñ¼®À» ¿ä±¸ÇÏÁö¸¸, ¿©±â¼´Â ´ÜÁö 1:50ÀÇ ºñÀ²·Î Ç÷¾×À» Èñ¼®ÇÑ´Ù. (2) ³ª´Â ¾ÆÁ÷ Èñ¼®ÇÏÁö ¾ÊÀº[1:1] °ßº»À» °¡Áö°í ÀÌ Å×½ºÆ®¸¦ ¼öÇàÇÒ ±âȸ¸¦ °®Áö ¸øÇß´Ù. 3. ³íÀÇ. ´ÙÀ½Àº ¿Ö Èñ¼®ÇÏÁö ¾ÊÀº Ç÷¾× °ßº»µéÀÌ Ç×»ó ELISA Å×½ºÆ®¿¡¼ ¾ç¼º ¹ÝÀÀÇÏ´Â °ÍÀΰ¡¿¡ ´ëÇÏ¿© °¡´É¼ºÀÌ ÀÖ´Â ¼¼ °¡Áö ¼³¸íÀÌ´Ù: 3.1. ´©±¸³ª°¡ HIV Ç×ü¸¦ °¡Áö°í ÀÖ´Ù. HIV¿¡ ´ëÇÑELISA Å×½ºÆ®°¡ Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º¶ó°í ¾Ë·ÁÁ® ÀÖ´Â °Í¿¡ ´ëÇÑ Ç×ü¸¦ ¹ß°ßÇÑ´Ù´Â °ÍÀº ¼¼°èÀûÀ¸·Î ÀÎÁ¤µÇ°í ÀÖ´Ù.(3-4-5-6) ±×¸®°í ELISA ŰƮ¸¦ »ó¾÷ÈÇÑ Á¦¾à ȸ»ç´Â ´ÙÀ½°ú °°ÀÌ ¸»ÇÑ´Ù. Abbott HIVAB HIV-1 EIA(È¿¼Ò¸é¿ªÃøÁ¤¹ý)´Â Àΰ£ Ç÷û°ú Ç÷Àå¿¡ ÀÖ´Â Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º ŸÀÔ 1(HIV-1)ÀÇ ¹ß°ßÀ» À§ÇÑ vitro qualitative Enzyme Immunoassay ÀÌ´Ù.(1) Èñ¼®ÇÏÁö ¾ÊÀº ¸ðµç Ç÷¾× °ßº»Àº ¼ÒÀ§ HIV¿¡ ´ëÇÑ Ç×ü¸¦ °Ë»çÇÑ´Ù´Â ELISA Å×½ºÆ®¿¡¼ ¾ç¼º ¹ÝÀÀÇϱ⠶§¹®¿¡ ÀÌ °á°ú´Â ¸ðµç Àΰ£Àº HIV Ç×ü¸¦ °¡Áö°í ÀÖ´Ù´Â °ÍÀ» ¾Ï½ÃÇÑ´Ù. ±×¸®°í À̰ÍÀº ´©±¸³ª HIV Ç׿ø¿¡ ³ëÃâµÇ¾ú´ø ÀûÀÌ ÀÖ´Ù´Â °ÍÀ» ¾Ï½ÃÇÑ´Ù. À̰ÍÀº ¿ì¸® ¸ðµÎ°¡ AIDSÀÇ ¿øÀÎ À̶ó°í ¹Ï¾îÁö´Â ¹ÙÀÌ·¯½º¿¡ ³ëÃâµÈ ÀûÀÌ ÀÖ´Ù´Â °ÍÀ» ÀǹÌÇÒ °ÍÀÌ´Ù. 1:400ÀÇ Èñ¼®¿¡¼Á¶Â÷ ¾ç¼º ¹ÝÀÀÇÏ´Â »ç¶÷Àº HIV Ç׿ø¿¡ °¡Àå ³ô°Ô ³ëÃâµÇ¾ú´ø »ç¶÷ÀÏ °ÍÀÌ´Ù. ³ª¸ÓÁö »ç¶÷µéÀº-Èñ¼®ÇÏÁö ¾ÊÀº Ç÷û[1:1]¿¡¼¸¸ ¾ç¼º ¹ÝÀÀÇÏ´Â »ç¶÷µé- HIV¿¡ ³ëÃâ Á¤µµ°¡ º¸´Ù ³·¾ÒÀ» °ÍÀÌ´Ù. 3.2. ´©±¸³ª »óÀÌÇÑ ¼öÁØÀ¸·Î HIV¿¡ °¨¿°µÇ¾î ÀÖ´Ù. ¶ÇÇÑ ¼¼°èÀûÀ¸·Î HIV Ç×ü¿¡ ´ëÇÏ¿© ¾ç¼º ¹ÝÀÀÇÏ´Â »ç¶÷Àº ¸é¿ª °áÇÌÀ» À¯¹ßÇÏ´Â Ä¡¸íÀûÀÎ ¹ÙÀÌ·¯½º¿¡ ³ëÃâµÈ ÀûÀÌ ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó ÇöÀç °¨¿°µÇ¾î ÀÖ´Ù°í ¹Ï¾îÁö°í ÀÖ´Ù.(3-4-5-6) µû¶ó¼ Èñ¼®ÇÏÁö ¾ÊÀº Ç÷ûÀÇ ¾ç¼º¹ÝÀÀÀº ¸ðµç »ç¶÷µé ¾Æ´Ï¸é ÃÖ¼ÒÇÑ ³»°¡ Å×½ºÆ®Çß´ø ³ª ÀÚ½ÅÀÇ °ÍÀ» Æ÷ÇÔÇÑ ¸ðµç Ç÷¾× »ùÇÃÀÌ ÀÌ Ä¡¸íÀûÀÎ ¹ÙÀÌ·¯½º¿¡ °¨¿°µÇ¾ú´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. 1:400ÀÇ ºñÀ²¿¡¼ ¾ç¼º ¹ÝÀÀÇÏ´Â »ç¶÷Àº Èñ¼®ÇÏÁö ¾ÊÀº Ç÷û¿¡¼¸¸ ¾ç¼º ¹ÝÀÀÇÏ´Â »ç¶÷ÀÌ °É¸° Ä¡¸íÀûÀÎ °¨¿°º¸´Ù ´Ù¸¸ ´õ ³ôÀº ¼öÁØÀÇ Ä¡¸íÀûÀÎ °¨¿°¿¡ °É·ÈÀ» °ÍÀÌ´Ù. 3.3 .Å×½ºÆ®´Â HIV¿¡ ƯÀÌÀûÀÌÁö ¾Ê´Ù. ¿©±â¼ Á¦½ÃµÈ °á°ú´Â ¾Æ¿ï·¯ Àü¿¡ ¼³¸íÇß´ø ¹Ù¿Í °°ÀÌ HIV Ç×ü¸¦ ¹ß°ßÇϱâ À§ÇÏ¿© »ç¿ëµÇ´Â Å×½ºÆ®°¡ HIV¿¡ ´ëÇÏ¿© ƯÀ̼ºÀ» °¡ÁöÁö ¾Ê´Â´Ù´Â °ÍÀ» ÀǹÌÇÒ ¼ö ÀÖ´Ù. (7-8-9-10-11-12-13-14) ÀÌ °æ¿ì ¿Ö ¾î¶² »ç¶÷Àº ±×°Í¿¡ ¾ç¼º ¹ÝÀÀÇϴ°¡¸¦ ¼³¸íÇϱâ À§ÇÏ¿© °ú°Å ȤÀº ÇöÀçÀÇ HIV °¨¿° À̿ܿ¡ ´Ù¸¥ ÀÌÀ¯°¡ ÀÖÀ» °ÍÀÌ´Ù. ±× Å×½ºÆ®´Â HIV°¡ Á¸ÀçÄ¡ ¾Ê¾Æµµ ¾ç¼º ¹ÝÀÀÇÑ´Ù.(7-8-9-10-11-12-13-14) °úÇÐ ¹®Çå¿¡´Â °ú°Å³ª ÇöÀçÀÇ HIV °¨¿° À̿ܿ¡µµ ¾ç¼º ¹ÝÀÀÀ» ¾ò°Ô µÇ´Â 70 °¡Áö ÀÌ»óÀÇ ´Ù¸¥ ÀÌÀ¯µéÀÌ ³ªÅ¸³ª ÀÖ´Ù. (7,10,11,14,15) À̵é Á¶°Ç ¸ðµÎ´Â °øÅëÀûÀ¸·Î ´ÙÁß Ç׿øÀû ÀÚ±ØÀÇ Àü·ÂÀ» °¡Áö°í ÀÖ´Ù. (15,16) Abbott ½ÇÇè½ÇÁ¶Â÷µµ ELISA Å×½ºÆ®°¡ °¡Áø ƯÀ̼º ¹®Á¦¸¦ Àß ¾Ë°í ÀÖ´Ù. À̰ÍÀÌ ±×µéÀÌ ´ÙÀ½°ú °°ÀÌ ¸»ÇÏ´Â ÀÌÀ¯ÀÌ´Ù. ¹ÝÀÀÇÏ´Â °ßº»¿¡ ´ëÇÑ ±Ç°í Á¶»ç ¹æ¹ýÀº HIV-1 Ç×ü°¡ Á¸ÀçÇÑ´Ù´Â ³ôÀº °¡´É¼ºÀ» ¾Ï½ÃÇÒÁö¶óµµ EIA(È¿¼Ò¸é¿ªÃøÁ¤¹ý) Å×½ºÆ® ´Üµ¶À¸·Î´Â AIDS¸¦ Áø´ÜÇϴµ¥ »ç¿ëµÉ ¼ö ¾ø´Ù. ¾Æ¿ï·¯ EIAÀÇ ÀÓ»óÀû ±×¸®°í °øÁß À§»ýÀû Àû¿ëÀ» À§Çؼ´Â ¿¬±¸ ´ë»óÀÚÀÇ HIV-1 °¨¿° À§Çè Á¤µµ¿Í Ç÷ûÀÇ ¹ÝÀÀ¼º Á¤µµ ¸ðµÎ°¡ ±× Å×½ºÆ®¸¦ ÇØ¼®Çϴµ¥ ÀÖ¾î¼ Á߿伺À» °®Áö¸¸ À̵éÀÇ »óÈ£ °ü°è´Â ºÒ¿ÏÀüÇÏ´Ù. µû¶ó¼ ´ëºÎºÐÀÇ °æ¿ì Ãß°¡ÀûÀ¸·Î º¸´Ù ƯÀ̼ºÀ» °¡Áö´Â ȤÀº º¸¿ÏÀûÀÎ Å×½ºÆ®¿¡ ÀÇÇÏ¿© ¹ÝÀÀÀûÀÎ °ßº»À» ¹Ýº¹ Á¶»çÇÏ´Â °ÍÀÌ Å¸´çÇÏ´Ù. (1) Èï¹Ì·Ó°Ôµµ ¿µ±¹°ú °°Àº ³ª¶ó¿¡¼´Â ´ÜÁö ELISA Å×½ºÆ®¿¡¸¸ ±Ù°ÅÇÏ¿© HIV »óŸ¦ Áø´ÜÇϰí ÀÖ´Ù. ±×·¯ÇÑ ³ª¶ó¿¡¼´Â Western blotÀ̳ª ¾î¶² ´Ù¸¥ Å×½ºÆ®µµ ÇÊ¿äÄ¡ ¾Ê´Ù. Á¤ÇØÁø Å×½ºÆ®ÀÇ ¹Î°¨¼º°ú ƯÀ̼ºÀ» È®¸³Çϴµ¥ ÀÖ¾î¼ À¯ÀÏÇÑ Å¸´çÇÑ ¹æ¹ýÀº Àý´ë ±âÁØÀ» µû¸£´Â °ÍÀÌ´Ù. ÇÏÁö¸¸ HIV°¡ µ¶¸³µÇ°í Á¤Á¦µÈ ¹ÙÀÌ·¯½ºÀû ½Çü·Î¼ ºÐ¸®µÈ ÀûÀÌ ¾ø±â ¶§¹®¿¡(17-18-19) HIV¿¡ ´ëÇÑ Àý´ë ±âÁØÀº Á¸ÀçÇÒ ¼ö°¡ ¾ø´Ù. ±× ´ë½Å HIV Ç×ü Å×½ºÆ®ÀÇ ¹Î°¨¼º°ú ƯÀ̼ºÀºHIV°¡ AIDSÀÇ ¿øÀÎÀ̶ó´Â °¡Á¤ÇÏ¿¡ ±Ù°ÅÇÏ¿© Á¤ÀǵǾú´Ù. AbbotÀÇ ¿¬±¸¿¡¼ AIDS ȯÀÚ¿¡°Ô´Â HIV-1 Ç×ü°¡ 100% ³ªÅ¸³´Ù´Â °¡Á¤¿¡ ±Ù°ÅÇÑ ¹Î°¨¼ºÀº 100%ÀÎ °ÍÀ¸·Î Ãß»êµÈ´Ù. (144¸íÀÇ È¯ÀÚ¸¦ Å×½ºÆ®ÇÏ¿´À½) ¾Æ¿ï·¯ ¹«ÀÛÀ§ ÇåÇ÷ÀÚ¿¡°Ô´Â HIV-1 Ç×ü°¡ ³ªÅ¸³ªÁö ¾Ê´Â´Ù´Â °¡Á¤¿¡ ±Ù°ÅÇÑ Æ¯À̼ºÀº(4,777¸íÀÇ ¹«ÀÛÀ§ ÇåÇ÷ÀÚ¸¦ Å×½ºÆ®ÇÏ¿´À½) 99.9%ÀÎ °ÍÀ¸·Î Ãß»êµÈ´Ù´Â °ÍÀ» º¸¿©ÁÖ°í ÀÖ´Ù. ÇöÀç·Î´Â Àΰ£ Ç÷¾×¿¡¼ HIV-1 Ç×üÀÇ Á¸Àç À¯¹«¸¦ ÀÔÁõÇÏ´Â ÀÎÁ¤µÈ Ç¥ÁØÀÌ ¾ø´Ù. µû¶ó¼ ¹Î°¨¼ºÀº AIDSÀÇ ÀÓ»ó Áø´Ü¿¡ ±Ù°ÅÇÏ¿© °è»êµÇ°í ƯÀ̼ºÀº ¹«ÀÛÀ§ ÇåÇ÷ÀÚ¿¡ ±Ù°ÅÇÏ¿© °è»ê µÇ¾ú´Ù. (1) ELISA Å×½ºÆ®°¡ HIV Ç×ü¿¡ ´ëÇÏ¿© ƯÀ̼ºÀ» °®´Â´Ù´Â ¾î¶² °úÇÐÀûÀÎ Áõ°Åµµ ¾ø±â ¶§¹®¿¡ ³óÃà Ç÷û¿¡ ÀÖ¾î¼ ELISA Å×½ºÆ®°¡ ¹ÝÀÀÇÑ´Ù´Â °ÍÀº ºñƯÀ̼º ȤÀº ´ÙÁß Æ¯À̼º Ç×üµéÀÌ Á¸ÀçÇÑ´Ù´Â °ÍÀ» ÀǹÌÇÒ °ÍÀÌ´Ù. (20) ÀÌ Ç×üµéÀº ¸ðµç Ç÷¾× »ùÇÿ¡ Á¸ÀçÇÒ ¼ö ÀÖ´Ù. ±×°ÍµéÀº HIV´Â ¹°·Ð ¾î¶² ¸®Æ®·Î¹ÙÀÌ·¯½º(retrovirus)¿Íµµ ¿¬°üÀÌ ¾ø´Â, ½ºÆ®·¹½º¿¡ ´ëÇÑ ÀÀ´äÀÇ °á°úÀÏ °¡´É¼ºÀÌ °¡Àå ³ô´Ù. (21,22) .ÀÌ °æ¿ì ¹ÝÀÀ Å×½ºÆ®´Â ½ºÆ®·¹½º ÀÚ±ØÃ¼ ȤÀº »êÈ(ß«ûù) ¸Å°³Ã¼¿¡ ³ëÃâµÈ Á¤µµ¸¦ ÃøÁ¤ÇÏ´Â °ÍÀÌ µÉ °ÍÀÌ´Ù. (15,16) ÇÇÇÒ ¼ö ¾ø´Â °á·ÐÀº HIV Ç×ü¿¡ ´ëÇÑ ¸ðµç ¾ç¼º ¹ÝÀÀÀº ´ÜÁö À§¾ç¼ºÀÏ µû¸§À̶ó´Â °ÍÀÌ´Ù. ¸¸ÀÏ ¾Æ¹«µµ HIV ¾ç¼ºÀÌ ¾Æ´Ï¶ó¸é ELISA Å×½ºÆ®¿¡¼ ¾ç¼º ¹ÝÀÀÇÏ´Â »ç¶÷µéÀº HIV°¡ ¾Æ´Ñ ±× ¹«¾ð°¡ ¶§¹®¿¡ ±×·± °ÍÀÌ´Ù. 4. HIV Ç×ü Å×½ºÆ®ÀÇ ÁøÁ¤ÇÑ Àǹ̸¦ ã±â À§ÇÑ Á¦¾È. ÀÌ Å×½ºÆ®ÀÇ Àǹ̸¦ ¹àÈ÷±â À§ÇÏ¿© ³ª´Â °£´ÜÇÑ ½ÇÇèÀ» Á¦¾ÈÇÑ´Ù. ¼¼ ±×·ìÀÇ »ç¶÷µé·ÎºÎÅÍ Ç÷¾×À» äÃëÇÏ¿© ³ô°Ô Èñ¼®ÇÑ »óÅÂ, Èñ¼®ÇÏÁö ¾ÊÀº »óÅ ±×¸®°í ±× Áß°£ÀÇ Æø ³ÐÀº ´Ù¾çÇÑ ¹üÀ§ÀÇ Èñ¼® »óÅ¿¡ ´ëÇÏ¿© Å×½ºÆ®¸¦ ¼öÇàÇÑ´Ù. ù¹øÂ° ±×·ìÀº ´Ù¾çÇÑ ¿¬·É ±×·ìÀ¸·Î ÀÌ·ç¾îÁø °Ç°ÇÑ »ç¶÷µéÀÌ´Ù. µÎ¹øÂ° ±×·ìÀº ÀüÅëÀûÀÎ AIDS À§Çè ±×·ì¿¡ ¼ÓÇÏ´Â »ç¶÷µéÀÌ´Ù. 3¹øÂ° ±×·ìÀº AIDS¿Í ¿¬°üÀÌ Àֱ⵵ ÇÏ°í ¾ø±âµµ ÇÑ ÀÓ»óÀû »óÅ¿¡ ÀÖ´Â »ç¶÷µéÀÌ´Ù. ¸ðµç ±×·ìµéÀº ELISA¿Í Western blot Å×½ºÆ® ¾çÂÊ ¸ðµÎ¸¦ ¹Þ´Â´Ù. Ãß°¡ÀûÀ¸·Î, ¸ðµç Ç÷¾× »ùÇÃÀºHIV¿¡ ´ëÇÑ viral load Å×½ºÆ®¸¦ ¹ÞÀ» ¼ö ÀÖÀ» °ÍÀÌ´Ù. ±×·± ½ÇÇèÀÇ °á°ú´Â ÀÌ Å×½ºÆ® ÃøÁ¤ ³»¿ëÀÌ ½ºÆ®·¹½º ÀÚ±ØÃ¼ ȤÀº »êÈ ¸Å°³Ã¼¿¡ÀÇ ³ëÃâ Á¤µµ¿Í ¿¬°üÀÌ ÀÖ´ÂÁö¸¦ °áÁ¤ÇÒ ¼ö ÀÖÀ» °ÍÀÌ´Ù. ¸¸ÀÏ ±×·¸´Ù¸é ±× Å×½ºÆ®µéÀº °³ÀÎÀÇ µ¶¼ºÈ Á¤µµ¿¡ ´ëÇÑ ÃøÁ¤ ¹æ¹ýÀ¸·Î½á ±× ¿ëµµ°¡ »ì¾Æ³¯ ¼ö ÀÖÀ» °ÍÀÌ´Ù. ³ª´Â ÀÌ ½ÇÇèÀ» ¼öÇàÇϴµ¥ ÇÊ¿äÇÑ °æÁ¦Àû Áö¿øÀ» Èñ¸ÁÇÑ´Ù. ÇÑÆí »ç¶÷µéÀº HIV¿¡ ƯÀÌÀûÀÌÁö ¾ÊÀº Å×½ºÆ®¿¡¼ ¾ç¼º ¹ÝÀÀÀ» ÇϹǷΠ±×µéÀ» HIV ¾ç¼ºÀÎÀ̶ó°í ºÐ·ùÇÏ´Â °ÍÀ» Áß´ÜÇÒ °ÍÀ» Á¦¾ÈÇÑ´Ù. °¨»çÀÇ ¸» Yorktown ÀÇÇÐ ½ÇÇè½Ç ½ÇÀåÀÎ Mr. Albert Padovani°¡ ±×ÀÇ ½ÇÇè½Ç¿¡¼ ¿©±â¿¡ ¹ßÇ¥ÇÑ ½ÇÇèÀ» ¼öÇàÇÒ ¼ö ÀÖµµ·Ï Çã¶ôÇϰí Å×½ºÆ®¸¦ À§ÇÑ ½Ã¾àÀ» Á¦°øÇÏ¿© ÁØ °Í¿¡ °¨»ç µå¸°´Ù. ¾Æ¿ï·¯ New York½Ã HEALÀÇ Tom Di Ferdinando »ç¹«ÃÑÀå¿¡°Ô ÀÌ ³í¼³¿¡ ´ëÇÑ ¿ø°í¸¦ ÆíÁýÇÏ°í ¼ÒÁßÇÑ Á¦¾ÈÀ» ÇØ °Í¿¡ ´ëÇÏ¿© °¨»ç¸¦ µå¸°´Ù. Roberto .Giraldo, ÀÇÇйڻç. ³»°ú ÀÇ»ç, ³»°ú Àü¿°¼º ¿´ë¼º Áúº´ Àü¹®ÀÇ. HIV-AIDS °¡¼³ÀÇ °úÇÐÀûÀÎ Àç°ËÅ並 À§ÇÑ ¸ðÀÓ°ú HEALÀÇ ÀÌ»çȸ ȸ¿ø. µ¶¸³Àû AIDS ¿¬±¸°¡. ¼Àû AIDS¿Í ½ºÆ®·¹½º ÀÚ±ØÃ¼ÀÇ ÀúÀÚ, ÀüÀÚ¸ÞÀÏ :rgiraldo@cdiusa.com . Âü°í ¹®Çå (1) ABBOT LABORATORIES. Human Immunodeficiency Virus Type 1. FUVAB FffVI EIA. Abbott Laboratories, 66-8805/R5, January 1997:5. (2) EPITOPE ORGANON TEKNIKA. Human Immunodeficiency Virus Type 1 (fuV-1) . I-UV-1 Western Blott Kit. PN201-3039 revision number 6. (3) FEINBERG MA & VOLBERDING PA. Testing for Human Immunodeficiency Virus. In: COHEN PT, SANDE MA and VOLBERDING PA. The AIDS Knowledge Base. Boston: Little, Brown and Company, 1994: section 2. (4) PINS MR. TERUYA and STOWELL CP. Human Immunodeficiency Virus Testing and Case Definition: Pragmatic and Technical Issues. In: COTTON D and WATTS DH. The Medical Management of AIDS in Women. New York. John Wiley & Sons, 1997: 163-176. (5) METCALF JA, DAVEY RT and LANE HC. Acquired Immunodeficiency Syndrome: Serologic and Virologic Tests. In DEVITA VT, CURRAN J, HELLMAN S, et al. AIDS: Etiology, Diagnosis, Treatment and Prevention. 4th Edition. Philadelphia: Lippincott-Raven, 1997: 177-196. (6) WEISS SH. Laboratory Detection of Human Retroviral Infections. In: WORMSER GP. AIDS and Other Manifestations of FUV Infection. New York: Lippincott-Raven, 1998:175-200. (7) PAPADOPULOS-ELEOPULOS, E., TURNER V. & PAPADIMITROU JM. Is a Positive Western Blott Proof of HIV Infection?. Bio/Technology 1993; 11:696-707. (8) PAPADOPULOS-ELEOPULOS, E., TURNER, V., PAPADIMITROU JM. & CAUSER D. HIV Antibodies: Further Questions and a Plea for Clarification. Curr Med Res Opin 1997; 13:627-634. (9) HODGKINSON N. Science Falls the «AIDS Test» In: AIDS: The Failure of Contemporary Science. How a Virus that Never Was Deceived the World. London: Fourth Estate, 1996:232-262. (10) JOHNSON C. Factors Known to Cause False-Positive HIV Antibody Test Results; Zenger's, San Diego, California, september 1996a:8-9. (11) JOHNSON C. Whose Anitbodies Are There Anyway?. Continuum (London) . September/october 1996b; 4(3) :4-5. (12) TURNER VF. Do Antibody Tests Prove HIV Infection?. Interview by Huw Christie Editor of Continuum. Continuum (London) Winter 1997/1998; 5(2) :10-19. (13) SHENTON J. Positively False: Wrong Tests and Long-Term Survivors. In: Positively False: Exposing the Myths around HIV and AIDS. London: I.B. Tauris, 1998: 238-239. (14) GIRALDO RA. Milking the Market. Will Mothers Dish Out the W.H.O. Formula?. Continuum (London) 1998; 5(4) :8-10. (15) PAPADOPULOS-ELEOPULOS E. Reappraisal of AIDS - Is the Oxidation Induced by the Risk Factors the Primary Cause?. Medical Hyphotesis 1988; 25:151-162. (16) GIRALDO RA. AIDS ans Stressors U: A Proposal for the Pathogenesis of AIDS. In: AIDS and Stressors. Medellín, Colombia: Impresos Begón, 1997: 57-96. (17) PAPADOPULOS-ELEOPULOS, E., TURNER, V., PAPADIMITROU JM. & CAUSER D. The Isolation of HIV: Has it Really Been Achieved?. The Case Against. Continuum (London) 1996; 4(3) :S1-S24. (18) LANKA S. No Viral Identification: No Cloning as Proof of Isolation. Continuum (London) 1997; 4(5) :31-33. (19) DE HARVEN E. Remarks on Methods for Retroviral Isolation. Continuum (London) 1998; 5(3) :20-21. (20) WING MG. The Molecular Basis for a Polyspecific Antibody. Clin Exp Immunol 1995; 99:313-315. (21) SNYDER HW and FLEISSNER E. Specificity of Human Antibodies to Oncovirus Glycoproteins: Recognition of Antigen by Natural Antibodies Directed Against Carbohydrate Structures. Proc Nat Acad Sci USA 1980; 77:1622-1626. (22) BARBACID K., BOLOGNESI D. & AARONSON SA. Humans Have Antibodies Capable of Recognizing Oncoviral Glycoproteins: Demonstration that These Antibodies are Formed in Response to Cellular Modification of Glycoproteins Rather than as Consequence of Exposure to Virus. Proc Nat Acad Sci USA 1980; 77:1627-1621. |
![]() ![]() ![]() ![]() ![]() ![]() |